Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans.
Previously, we evaluated 2 doses of H5N1 influenza vaccine in persons 18-64 years of age (placebo and 7.5-, 15-, 45-, or 90-microg doses), separated by 28 days. In this study, 337 participants received a third dose, 6 months thereafter. Microneutralization (MN) and hemagglutination-inhibition geometric mean titers (GMTs) of antibody declined before the third dose. Twenty-eight days after the third dose, 78%, 67%, 43%, and 31% of recipients in the 90-, 45-, 15-, and 7.5-mug-dose groups had a MN GMT > or =1:40, respectively. Five months later, MN GMTs were significantly greater than those after the second dose. (


BACKGROUND
Clinical Trials.gov identifier NCT00240968 .).
Zangwill
Kenneth M
KM
University of California, Los Angeles, CA, USA. kzangwill@labiomed.org
Treanor
John J
JJ
Campbell
James D
JD
Noah
Diana L
DL
Ryea
Jennifer
J
D000328:Adult; D005260:Female; D006801:Humans; D007115:Immunization Schedule; D007117:Immunization, Secondary; D007156:Immunologic Memory; D053124:Influenza A Virus, H5N1 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000009:adverse effects / Q000276:immunology*; D007251:Influenza, Human / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D015164:Vaccines, Inactivated / Q000276:immunology
D007252:Influenza Vaccines; D015164:Vaccines, Inactivated